2025 Europe Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report
Description
The 2025 Europe Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer immunotherapy drug discovery outsourcing market in Europe include Labcorp Holdings Inc., Eurofins Scientific SE, Horizon Discovery Group plc, and Genscript Biotech Corp. Labcorp and Eurofins offer extensive contract research services, including preclinical and clinical testing tailored to immunotherapy drug discovery. Horizon Discovery focuses on gene editing and cellular modeling technologies that enhance immunotherapy target validation. Genscript provides custom biologics and antibody engineering solutions essential for immuno-oncology drug development. These companies collectively drive the European market, valued at approximately $698 million by 2030, fueled by increasing R&D outsourcing and specialized cancer immunotherapy drug development demands.
Additional key players in the broader global cancer immunotherapy drug discovery outsourcing market include Adaptimmune and ADC Therapeutics, both European-based firms. Adaptimmune, UK-based, pioneers enhanced T-cell therapies targeting solid tumors, leveraging SPEAR T cell technology. ADC Therapeutics and NBE Therapeutics focus on antibody-drug conjugates, combining monoclonal antibodies with cytotoxic payloads for targeted cancer therapy, crucial in outsourcing drug discovery processes. The outsourcing market benefits from these firms' innovative platforms, supporting faster development of immune-based cancer treatments across Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer immunotherapy drug discovery outsourcing market in Europe include Labcorp Holdings Inc., Eurofins Scientific SE, Horizon Discovery Group plc, and Genscript Biotech Corp. Labcorp and Eurofins offer extensive contract research services, including preclinical and clinical testing tailored to immunotherapy drug discovery. Horizon Discovery focuses on gene editing and cellular modeling technologies that enhance immunotherapy target validation. Genscript provides custom biologics and antibody engineering solutions essential for immuno-oncology drug development. These companies collectively drive the European market, valued at approximately $698 million by 2030, fueled by increasing R&D outsourcing and specialized cancer immunotherapy drug development demands.
Additional key players in the broader global cancer immunotherapy drug discovery outsourcing market include Adaptimmune and ADC Therapeutics, both European-based firms. Adaptimmune, UK-based, pioneers enhanced T-cell therapies targeting solid tumors, leveraging SPEAR T cell technology. ADC Therapeutics and NBE Therapeutics focus on antibody-drug conjugates, combining monoclonal antibodies with cytotoxic payloads for targeted cancer therapy, crucial in outsourcing drug discovery processes. The outsourcing market benefits from these firms' innovative platforms, supporting faster development of immune-based cancer treatments across Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
